Snow Capital Management LP increased its holdings in Amgen (NASDAQ:AMGN) by 1.3% in the 4th quarter, HoldingsChannel reports. The firm owned 52,381 shares of the medical research company’s stock after buying an additional 654 shares during the quarter. Snow Capital Management LP’s holdings in Amgen were worth $9,109,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. Janus Henderson Group PLC increased its holdings in shares of Amgen by 3,664.7% during the second quarter. Janus Henderson Group PLC now owns 3,699,351 shares of the medical research company’s stock worth $637,139,000 after buying an additional 3,601,087 shares in the last quarter. FMR LLC increased its holdings in shares of Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after buying an additional 2,587,041 shares in the last quarter. Amundi Pioneer Asset Management Inc. increased its holdings in shares of Amgen by 382.3% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 1,389,775 shares of the medical research company’s stock worth $241,682,000 after buying an additional 1,101,649 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Amgen by 40.9% during the second quarter. Renaissance Technologies LLC now owns 3,400,145 shares of the medical research company’s stock worth $585,607,000 after buying an additional 986,700 shares in the last quarter. Finally, Nordea Investment Management AB increased its holdings in shares of Amgen by 12.9% during the second quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after buying an additional 806,119 shares in the last quarter. 79.54% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

AMGN has been the subject of several recent analyst reports. Argus raised shares of Amgen from a “hold” rating to a “buy” rating and raised their price objective for the stock from $192.33 to $220.00 in a report on Tuesday, January 23rd. Citigroup lowered shares of Amgen to a “neutral” rating in a report on Monday, December 18th. JPMorgan Chase reaffirmed a “hold” rating and set a $191.00 price objective on shares of Amgen in a report on Sunday, February 4th. Mizuho set a $192.00 price objective on shares of Amgen and gave the stock a “buy” rating in a report on Friday, December 22nd. Finally, Vetr lowered shares of Amgen from a “buy” rating to a “hold” rating and set a $184.25 price objective for the company. in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $190.57.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $189.75, for a total value of $289,368.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 4,575 shares of company stock worth $818,330. Insiders own 0.19% of the company’s stock.

Shares of AMGN stock opened at $171.38 on Tuesday. Amgen has a 52-week low of $152.16 and a 52-week high of $201.23. The company has a market capitalization of $114,595.02, a price-to-earnings ratio of 13.63, a price-to-earnings-growth ratio of 2.10 and a beta of 1.36. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.84 billion. During the same period in the previous year, the business posted $2.89 earnings per share. Amgen’s revenue was down 2.7% compared to the same quarter last year. equities analysts anticipate that Amgen will post 13.26 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a yield of 3.08%. Amgen’s payout ratio is presently 41.97%.

Amgen declared that its Board of Directors has authorized a share repurchase program on Thursday, February 1st that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

TRADEMARK VIOLATION NOTICE: “Snow Capital Management LP Acquires 654 Shares of Amgen (AMGN)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.dailypolitical.com/2018/04/17/snow-capital-management-lp-acquires-654-shares-of-amgen-amgn.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.